Preclinical testing of the Akt inhibitor triciribine in T‐cell acute lymphoblastic leukemia

Over the past 20 years, survival rates of T-cell acute lymphoblastic leukemia (T-ALL) patients have improved, mainly because of advances in polychemotherapy ...